Product Description: Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity[1][2].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Blumberg LJ, et al. Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses. Sci Adv. 2019 Dec 18;5(12):eaax9586. /[2]Blumberg L, et al. SYNT001: a humanized IgG4 monoclonal antibody that disrupts the interaction of FcRn and IgG for the treatment of IgG-mediated autoimmune diseases[J]. Blood, 2017, 130: 3483.
CAS Number: 2066544-85-0
Molecular Weight: N/A
Compound Purity: 98.45
Research Area: Inflammation/Immunology
Solubility: 10 mM in DMSO
Target: Others
English
Deutsch
